Rubius Therapeutics (NASDAQ:RUBY – Get Rating) announced its quarterly earnings results on Tuesday. The company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.01), MarketWatch Earnings reports. During the same period in the prior year, the firm earned ($0.51) earnings per share.
RUBY stock traded up $0.04 during trading on Thursday, hitting $1.32. The company had a trading volume of 4,934 shares, compared to its average volume of 1,215,533. The firm has a market cap of $119.05 million, a PE ratio of -0.57 and a beta of 2.84. Rubius Therapeutics has a 1-year low of $1.18 and a 1-year high of $29.06. The firm has a 50-day moving average price of $3.62 and a 200-day moving average price of $7.87. The company has a quick ratio of 6.63, a current ratio of 6.63 and a debt-to-equity ratio of 0.43.
In related news, Director David R. Epstein purchased 30,000 shares of the company’s stock in a transaction that occurred on Thursday, April 21st. The shares were purchased at an average price of $1.44 per share, for a total transaction of $43,200.00. Following the transaction, the director now directly owns 4,720,012 shares of the company’s stock, valued at approximately $6,796,817.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 52.60% of the company’s stock.
A number of analysts have issued reports on the company. SVB Leerink decreased their price target on Rubius Therapeutics from $5.00 to $3.00 and set a “market perform” rating for the company in a report on Monday, April 11th. HC Wainwright decreased their price target on Rubius Therapeutics from $15.00 to $8.00 in a report on Wednesday. Zacks Investment Research downgraded Rubius Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, February 22nd. Guggenheim reduced their target price on Rubius Therapeutics from $25.00 to $5.00 and set a “buy” rating for the company in a report on Monday, April 11th. Finally, Morgan Stanley reduced their target price on Rubius Therapeutics from $15.00 to $4.00 and set an “equal weight” rating for the company in a report on Monday, April 11th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $6.20.
Rubius Therapeutics Company Profile (Get Rating)
Rubius Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes.
- Get a free copy of the StockNews.com research report on Rubius Therapeutics (RUBY)
- Dutch Bros Gets Scalded By Inflation
- The S&P 500 Could Fall Another 28%
- Corning Stock is a Technology Value Play
- Anheuser-Busch InBev May Need One More Quarter to Confirm a Buy Signal
- Wolverine Worldwide Is Ready To Rebound
Receive News & Ratings for Rubius Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rubius Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.